Kristi Rosa

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

The same high cure rates achieved with preoperative chemoradiation can be achieved with preoperative FOLFOX, according to Deb Schrag, MD, FASCO, MPH.

Further dose optimization is ongoing in the phase 1 study of BI 764532 following the read-out of positive results.

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.

According to follow-up data from EMPOWER-Lung 3, cemiplimab plus platinum-doublet chemotherapy maintained clinically improvements in advanced non–small cell lung cancer.

Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

High-dose IL-2 is approved for use as a single agent in patients with metastatic melanoma. However, the agent induces limited efficacy and is known to have considerable toxicity.

Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.

At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.

While JCAR021 showed durable responses, there was a high rate of neurotoxicity when given at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma.

In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall survival rates vs those given intense salvage chemotherapy first.

In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.

SWOG 1815, which was investigating nab-paclitaxel plus gemcitabine and cisplatin, has missed its primary end point.

CheckMate-649 study findings continue to support frontline nivolumab and chemotherapy for patients with advanced gastric, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Positive results were shown with ziftomenib monotherapy in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.

During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.

According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.

Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.

Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.

Updated findings from the phase 3 ADAURA trial showed a significant disease-free survival improvement with the use of adjuvant osimertinib compared with placebo in patients with EGFR-mutated, stage I to IIIA non–small cell lung cancer.

Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.

The AMEERA-3 trial failed to meet its primary end point of superior progression-free survival for amcenestrant compared with endocrine therapy in patients with endocrine-resistant, ER-positive advanced breast cancer.

The phase 2 CARTITUDE study showed encouraging response in the heavily-pretreated multiple myeloma population. Now, the phase 3 CARTITUDE-4 trial is underway.

The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.

Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.

Data from the planned interim analysis of the FLAIR trial show that venetoclax plus ibrutinib can achieved minimal residual disease negativity in patient with treatment-naïve chronic lymphocytic leukemia.

The combination of botensilimab and balstilimab showed robust response rate, durability, and tolerability in a patients with microsatellite stable colorectal cancer.